STOCK TITAN

Globus Medical Announces First Surgeries with Revolutionary CREO ONE™ Robotic Screw

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Globus Medical, a leading musculoskeletal solutions company, has launched CREO ONE, the first robotic screw designed for spine surgery with ExcelsiusGPS. This innovative screw enhances the modular pedicle screw platform by simplifying procedures while boosting pullout strength by 86%. The unique awl-style tip allows for streamlined operations, eliminating traditional tapping methods. CREO ONE is compatible with existing CREO navigation instruments, marking a significant advancement in robotic spine surgery.

Loading...
Loading translation...

Positive

  • Launch of CREO ONE screw marks a significant advancement in robotic spine surgery.
  • Improves operational efficiency by reducing procedural steps and enhancing navigational accuracy.
  • Pullout strength increased by 86% compared to traditional screws, offering greater reliability.

Negative

  • None.
Argus Session date unavailable
+0.14% session move Open Argus
Details

News Market Reaction – GMED

The recorded move for GMED in the trading session of this news was +0.14%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

The Latest Enhancement to Robotically Navigated Spine Surgery with ExcelsiusGPS® 

AUDUBON, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the recent launch of CREO ONE™, the market’s first robotic screw designed for spine surgery with ExcelsiusGPS®.

CREO ONE™ enhances the company’s groundbreaking modular pedicle screw platform by simplifying pedicle preparation while maintaining navigational accuracy and increasing pullout strength by 86% compared to traditional pedicle screws tapped to size. The screw is the first of its kind to offer this level of advanced robotic integration, streamlined workflow, and pullout strength. 

The CREO ONE™ screw’s unique tip may save time and improve efficiency in the OR by reducing procedural steps. “The screw completely eliminates the need to tap and simply requires a starting, pilot hole to break the cortex prior to placing the vertebral pedicle screw, further streamlining the operative workflow while increasing screw pullout strength,” said Dr. Frank La Marca, neurosurgeon in Jackson, Michigan. “The awl-style tip helps the screw follow a pre-planned trajectory and gives me the confidence of maintained navigational accuracy without performing traditional pedicle preparation. This makes the entire procedure easier and more reliable.”

CREO ONE™ is part of the CREO AMP® family. CREO ONE™ screws are compatible with CREO MIS® and CREO AMP® screw heads, and use existing CREO® navigation instruments. 

To learn more, visit GlobusMedical.com/products/CREO-One.

About Globus Medical, Inc. 
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com. 

Safe Harbor Statements 
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact: 
Brian Kearns 
Senior Vice President, Business Development and Investor Relations 
Phone: (610) 930-1800 
Email: investors@globusmedical.com 
www.globusmedical.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is CREO ONE from Globus Medical?

CREO ONE is the first robotic screw designed for spine surgery, offering enhanced operational efficiency and increased pullout strength.

How does CREO ONE improve spine surgery procedures?

CREO ONE simplifies pedicle preparation, eliminates the need for traditional tapping, and enhances navigational accuracy.

What advantages does CREO ONE offer compared to traditional screws?

It increases pullout strength by 86%, improves procedural efficiency, and streamlines the surgical workflow.

When was the CREO ONE launched by Globus Medical?

CREO ONE was launched on April 15, 2021.

Is CREO ONE compatible with existing Globus Medical products?

Yes, CREO ONE is compatible with CREO MIS and CREO AMP screw heads, as well as existing CREO navigation instruments.

Keep reading